{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-036367","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.048516+00:00","generated_at":"2026-06-22T14:54:57.793364+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sana Biotechnology reports Q3 net loss $85.1M; cash $511.6M; pipeline IND timeline updates","bullets":["Net loss of $85.1M ($0.45 per share) vs $83.3M ($0.46 per share) in Q3 2021; cash, cash equivalents and marketable securities $511.6M at Sep 30, 2022.","Cash runway expected into 2025; operating cash burn $219.8M for nine months ended Sep 30, 2022.","SC291 (allogeneic CAR T) IND filing on track for 2022 with clinical data expected in 2023.","SG295 (in vivo CAR T) IND filing delayed to 2023 to incorporate second-generation process with 50X potency improvement.","SC276 IND on track for 2023; SC451 (type 1 diabetes cell therapy) IND expected in 2024 with data in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-036367","json":"https://secwatch.observer/filing/0001564590-22-036367.json","markdown":"https://secwatch.observer/filing/0001564590-22-036367.md","text":"https://secwatch.observer/filing/0001564590-22-036367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000156459022036367/0001564590-22-036367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000156459022036367/sana-8k_20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:54:57.793364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfa8ac6383c33c0b8133e7141c96a77531e22c23","claim":"Sana Biotechnology, Inc. reported financial results for the quarter and year ended September 30, 2022.","evidence_excerpt":"On November 2, 2022, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000156459022036367/0001564590-22-036367-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}